Brazil's public health system, known as SUS, has begun offering three new high-technology medicines for treating lung cancer, according to Jornal da USP. The change was reported on Monday, 5 October 2026.
Jornal da USP reports that the three drugs are now available through the public system. The outlet's coverage includes guidance on which medicines are involved and how patients can request them, though the specific drug names were not detailed in the available summary.
The move comes amid broader attention to lung cancer in Brazil. Other outlets covering the same development note that the disease's advance has made early diagnosis and new treatments a growing focus. One report also highlights that lung cancer is the type that kills the most men worldwide, a point raised in coverage tied to Brazil's Day of the Older Person.
Separately, another report in the same summary states that SUS patients may have access to video-assisted surgery for lung cancer. That item appeared alongside the coverage of the new medicines, pointing to a wider set of changes in how the public system handles the disease.
The reporting does not specify eligibility criteria, cost, or the manufacturers of the three medicines. It also does not state how many patients are expected to benefit.
What to watch next: whether SUS publishes formal guidance on eligibility and how patients can access the newly listed treatments.
